Eisai to Launch Parkinson s Disease Treatment Equfina in South Korea
TOKYO, Feb 1, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that Eisai Korea Inc., Eisai s subsidiary in South Korea, has launched the Parkinson s disease treatment Equfina (safinamide mesilate, safinamide ). This is the first launch of Equfina in the Asian region excluding Japan.
The estimated number of patients with Parkinson s disease is approximately 150,000 in South Korea. Parkinson s disease has high unmet medical needs because of inadequate symptom control using current medications, necessitating new treatment options. This disease is designated as a rare intractable disease in South Korea.
The marketing approval of this drug in South Korea is primarily based on a double-blind, placebo-controlled, Phase III Study (SETTLE study) conducted overseas (including South Korea) to evaluate the efficacy and safety of 24-week oral administration of the once-daily safinamide as an add-on to levodopa in pat
Researchers design proton trap that delivers drugs at desired location in nervous system
February 01, 2021
New technique may reduce side-effects of the drugs; in the long term, ion pumps may help patients of neurological diseases for which effective treatments are not available Researchers at Linköping University, Sweden, have designed a proton trap that makes organic electronic ion pumps more precise when delivering drugs.
According to the researchers, this new technique may reduce the side-effects of the drugs. They also believe that in the long term, ion pumps may help patients with symptoms of neurological diseases for which effective treatments are not available.
Certain kinds of bacteria change their shape in order to adapt to long-term exposure to antibiotics, according to the study published in the journal Nature Physics.The study stated that the bacteria t
Editor's note: Djoomart Otorbaev is the former Prime Minister of the Kyrgyz Republic, a distinguished professor of the Belt and Road School of Beijing Normal University, and a member of Nizami Ganjavi International Center. The article reflects the author's views, and not necessarily those of CGTN.